Breaking Down Barriers to Diabetes Self-Care

Completed · Not applicable

Conditions studied: Type 1 Diabetes, Type 2 Diabetes

In brief

Performance of self-care recommendations is key to the successful treatment of diabetes. However, many patients have difficulty adhering to diabetes self-care recommendations. Recent results from our own studies and others have identified specific barriers to diabetes self-care. To evaluate the efficacy of a diabetes educator-led group intervention, the Breaking Down Barriers Program, that addresses barriers and therefore leads to improved adherence to diabetes self-care recommendations, we will randomize 222 (111 type 1 and 111 type 2) diabetes patients to one of three conditions: 1) the Breaking Down Barriers Program, 2) a cholesterol attention control condition, or 3) a 'usual care' control condition. We hypothesize that those assigned to the Breaking Down Barriers group will improve self-care behaviors and glycemic control more than those in the two control groups. We will follow study subjects for one year to determine whether their self-care behaviors and glycemic control improved and if the improvement was maintained over time.

Key facts

Study ID

NCT00142922

Run by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

People needed

222

Starts

2002-10-01

Expected to finish

2007-10-01

Last updated by the study team

2010-03-02

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• For Patients With Type 1 Diabetes
• Aged 18-65
• Presence of type 1 diabetes mellitus.
• 2-25 year duration.
• For Patients With Type 2 Diabetes
• Aged 25-65 years
• presence of type 2 diabetes mellitus.
• 2 years since initial diagnosis.

You may not qualify if…

• Renal disease, microalbumin >300 ug/mg)
• Severe peripheral diabetic neuropathy and/or severe peripheral vascular disease
• Symptomatic severe autonomic neuropathy who may be at risk when increasing activity levels.
• Women who are currently pregnant
• proliferative diabetic retinopathy based on dilated eye examination within one year of study entry. Patients whose eye disease is successfully treated will be included.
• HbA1c levels less than 7.0% (normal range 4.0 - 6.0%).
• HbA1c levels greater than 14.0%
• patients who underwent intensive insulin treatment within one year
• a history of severe, unstable myocardial infarction, congestive heart failure or other severe cardiac disease, severe hypertension (systolic more than 160 mmHg or diastolic 90 mmHg) who may be at risk when mildly increasing physical activity
• a DSMIV diagnosis of eating disorders including anorexia nervosa, bulimia, and severe weight-related insulin omission.
• Patients with recent diagnosis (past 6 months) of bipolar disorder, schizophrenia, mental retardation, organic mental disorder, and alcohol or drug abuse
• Patients whose diabetes diagnosed cannot be clearly classified as type 1 or type 2.

Where it is running

• Joslin Diabetes Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.